B. Riley Has Pessimistic Outlook of Novavax Q3 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at B. Riley cut their Q3 2025 earnings per share (EPS) estimates for shares of Novavax in a research note issued on Wednesday, October 29th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings of ($1.47) per share for the quarter, down from their previous estimate of ($0.70). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax’s Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at $1.19 EPS, FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $0.27 EPS and FY2029 earnings at $0.78 EPS.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The business had revenue of $239.24 million during the quarter, compared to analyst estimates of $149.19 million. During the same period in the previous year, the firm earned $0.99 EPS. Novavax’s quarterly revenue was down 42.4% compared to the same quarter last year.

Several other equities analysts have also issued reports on NVAX. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novavax in a research report on Wednesday, October 8th. Bank of America reiterated an “underperform” rating and issued a $7.00 price objective (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. HC Wainwright upped their price target on Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Cantor Fitzgerald started coverage on Novavax in a research report on Friday, October 24th. They set an “overweight” rating and a $18.00 price target for the company. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $11.33.

Novavax Price Performance

Shares of NVAX opened at $8.40 on Friday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.34 and a current ratio of 2.36. The stock has a 50 day simple moving average of $8.38 and a 200 day simple moving average of $7.51. Novavax has a 52-week low of $5.01 and a 52-week high of $11.55. The firm has a market capitalization of $1.36 billion, a PE ratio of 3.68, a P/E/G ratio of 0.12 and a beta of 2.74.

Institutional Investors Weigh In On Novavax

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Novavax by 11.0% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 12,755 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 1,268 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Novavax by 2.3% during the second quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 1,718 shares in the last quarter. SBI Securities Co. Ltd. boosted its stake in shares of Novavax by 5.5% during the second quarter. SBI Securities Co. Ltd. now owns 34,095 shares of the biopharmaceutical company’s stock valued at $215,000 after purchasing an additional 1,766 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in shares of Novavax by 9.0% during the second quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 2,326 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Novavax by 2.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after purchasing an additional 2,750 shares in the last quarter. Institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.